Saltigo to showcase portfolio at Chemspec Europe

Published: 10-Jun-2008

Saltigo, a global service provider for custom synthesis and custom manufacturing, is set to showcase its product portfolio at Chemspec Europe 2008 next week.


Saltigo, a global service provider for custom synthesis and custom manufacturing, is set to showcase its product portfolio at Chemspec Europe 2008 next week.

The wholly-owned subsidiary of specialty chemicals group LANXESS AG offers tailor-made solutions for customers from the crop protection sector to pharmaceutical industries.

The company will use its presence at the exhibition to detail its expertise in areas, including developing and optimising chemical syntheses, the piloting and upscaling of existing processes and the large-scale production of complex molecules.

A worldwide network of experienced experts offers comprehensive expertise in managing sophisticated reaction steps and sequences, e.g. asymmetrical, catalytic hydrogenation, reactions at low temperatures (down to -100 °C) or under high pressure. Compounds with azides, hydrocyanic acid, fluorine and phosgene are also handled reliably and safely. With a comprehensive reaction and technology portfolio, projects can either be based on existing technical packages or on newly developed, customised synthesis routes. This

set up means that a whole range of substances can be delivered reliably and cost-effectively on virtually any scale -from just a few kilograms to several hundred tons. The insect repellant Saltidin is one example of Saltigo's portfolio.

Saltidin is the new trade name for the proven active ingredient Icaridin, which was previously marketed as Bayrepel. The product does not leave a sticky film on the skin once they have been rubbed in. Nor does it emit an unpleasant smell.

Diana Rudolph, who has global responsibility for the Saltidin business, said: "This state-of-the-art insect repellent, which is recommended by the World Health Organization (WHO), has been helping to combat deadly diseases such as malaria and yellow fever since it was first launched on the market in 1998."

You may also like